NEW YORK, June 16, 2026, 16:26 (EDT)
- SRXH traded near $0.1891, up roughly 20%. Shares moved between $0.148 and $0.2096 on strong volume.
- SRx and EMJ Crypto Technologies said June 8 they took a 4.99% stake in Smartkem and picked up some convertible preferred securities, according to a statement.
- Execution risk is still the key point. The all-stock EMJX deal for SRx has to meet closing conditions, SEC paperwork, and get NYSE American listing approval.
SRx Health Solutions Inc. shares surged Tuesday, pushing higher as the NYSE American-traded stock kept up its recent volatile run. Investors watched the company’s ongoing move toward EMJ Crypto Technologies and digital-asset treasury management. SRXH closed at roughly $0.19, up 21% at 4 p.m. in New York, according to Google Finance. Volume came in at 176.3 million shares, well above the average of 46.2 million.
SRx is seeing its trading pattern shift. It’s no longer acting as a typical small pet-health stock, but instead is behaving like a stand-in for a planned crypto-treasury platform. That means the corporate balance sheet would hold or run cryptocurrencies and digital assets, as opposed to sticking with cash and short-term investments.
Eric Jackson, a fund manager and activist investor, is expected to lead a crypto treasury firm via a reverse merger with SRx, Reuters said in December. Jackson’s firm, EMJX, plans to run a multi-asset portfolio and use hedging, setting itself apart from rivals like Strategy Inc. He said the plan is to “reinvest capital back into the treasury” instead of relying on dilution. Reuters
SRx and EMJX last week said they bought 4.99% of Smartkem Inc., a Nasdaq-listed advanced materials firm. They did the deal through a shelf takedown and picked up convertible preferred securities via private placement.
SRx and EMJX updated their portfolio on May 29, saying they started a position in Uber Technologies Inc., cut a long in Compass Inc., reduced some short bitcoin bets and brought in some international hedges. Michael Young from SRx’s board called it a “more cautious posture.” Jackson said the platform is meant to “protect capital” if market stress picks up. GlobeNewswire
SRx posted a 23% jump in fiscal Q2 revenue to $3.4 million for the quarter ended March 31. Net loss improved to $6.4 million, while cash was $20.5 million. CEO Kent Cunningham called the balance sheet “materially strengthened” and said SRx was keeping a focus on “disciplined capital allocation.” The operating picture is still light. GlobeNewswire
But the rally could turn. The EMJX deal, a planned all-stock move worth about $55 million, still needs stockholder approvals, SEC filings, and a nod from NYSE American for the new shares. Dilution is still front and center — adding shares cuts each holder’s stake.
Trading overhang remains a factor. A June prospectus supplement registered as many as 187.5 million common shares for resale from selling stockholders. Another filing cited by the company listed even higher resale potential tied to Keystone Capital Partners. It doesn’t guarantee all those shares hit the market, but the overhang can press on sentiment when the stock moves on volume and news.
SRx is still under review by NYSE American. In January, the company said the exchange had signed off on its compliance plan, aiming to meet listing standards by July 14, 2026.
NYSE American trades from 9:30 a.m. to 4 p.m. ET, then stays open for late trading until 8 p.m. ET. U.S. markets are set to close Friday, June 19 for Juneteenth, so traders could have less time this week to adjust positions.
